Show simple item record

dc.contributor.authorMartínez-Vélez, N
dc.contributor.authorGarcia-Moure, M
dc.contributor.authorMarigil, M
dc.contributor.authorGonzález-Huarriz, M
dc.contributor.authorPuigdelloses, M
dc.contributor.authorGallego Pérez-Larraya, J
dc.contributor.authorZalacaín, M
dc.contributor.authorMarrodán, L
dc.contributor.authorVarela-Guruceaga, M
dc.contributor.authorLaspidea, V
dc.contributor.authorAristu, JJ
dc.contributor.authorRamos, LI
dc.contributor.authorTejada-Solís, S
dc.contributor.authorDíez-Valle, R
dc.contributor.authorJones, C
dc.contributor.authorMackay, A
dc.contributor.authorMartínez-Climent, JA
dc.contributor.authorGarcía-Barchino, MJ
dc.contributor.authorRaabe, E
dc.contributor.authorMonje, M
dc.contributor.authorBecher, OJ
dc.contributor.authorJunier, MP
dc.contributor.authorEl-Habr, EA
dc.contributor.authorChneiweiss, H
dc.contributor.authorAldave, G
dc.contributor.authorJiang, H
dc.contributor.authorFueyo, J
dc.contributor.authorPatiño-García, A
dc.contributor.authorGomez-Manzano, C
dc.contributor.authorAlonso, MM
dc.date.accessioned2019-06-07T10:44:06Z
dc.date.issued2019-05-28
dc.identifier.citationNature communications, 2019, 10 (1), pp. 2235 - ?
dc.identifier.issn2041-1723
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3257
dc.identifier.eissn2041-1723
dc.identifier.doi10.1038/s41467-019-10043-0
dc.description.abstractPediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic approach. Delta-24-RGD is a replication competent adenovirus engineered to replicate in tumor cells with an aberrant RB pathway. This virus has proven to be safe and effective in adult gliomas. Here we report that the administration of Delta-24-RGD is safe in mice and results in a significant increase in survival in immunodeficient and immunocompetent models of pHGG and DIPGs. Our results show that the Delta-24-RGD antiglioma effect is mediated by the oncolytic effect and the immune response elicited against the tumor. Altogether, our data highlight the potential of this virus as treatment for patients with these tumors. Of clinical significance, these data have led to the start of a phase I/II clinical trial at our institution for newly diagnosed DIPG (NCT03178032).
dc.formatElectronic
dc.format.extent2235 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectCell Line, Tumor
dc.subjectAnimals
dc.subjectHumans
dc.subjectMice
dc.subjectAdenoviridae
dc.subjectGlioma
dc.subjectBrain Neoplasms
dc.subjectBrain Stem Neoplasms
dc.subjectDisease Models, Animal
dc.subjectXenograft Model Antitumor Assays
dc.subjectCell Survival
dc.subjectComputer Simulation
dc.subjectOncolytic Virotherapy
dc.subjectOncolytic Viruses
dc.subjectNeoplasm Grading
dc.subjectIn Vitro Techniques
dc.titleThe oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.
dc.typeJournal Article
dcterms.dateAccepted2019-04-16
rioxxterms.versionofrecord10.1038/s41467-019-10043-0
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-05-28
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNature communications
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team
pubs.publication-statusPublished
pubs.volume10
pubs.embargo.termsNot known
icr.researchteamGlioma Teamen_US
dc.contributor.icrauthorJones, Chrisen
dc.contributor.icrauthorMackay, Alanen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0